
Opinion|Videos|April 28, 2025
The Treatment Landscape for cGVHD: From Current Practices to Evolving Therapies
Author(s)Nelson Chao, MD, MBA
A panelist discusses how the treatment landscape for chronic graft-vs-host disease (cGVHD) has evolved significantly in recent years, with several pivotal clinical trials beyond REACH3 informing our approach, including the REACH1 and REACH2 trials for acute GVHD; the ROCKstar trial supporting belumosudil approval; and studies evaluating ibrutinib, axatilimab, and extracorporeal photopheresis.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please review the treatment landscape; how do other trials inform treatment?
- What other treatment strategies are available?
- Which patients do you think are best suited to receive ruxolitinib therapy?
- Where do you think the future of cGVHD treatment is heading?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5
































